Martin Wehling

List of Publications by Year
in descending order

62	2,207	279487	233125
papers	citations	23 h-index	45 g-index

73	73	73	2314
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Deprescribing or represcribing: not just a semantic dilemma. European Geriatric Medicine, 2022, 13, 529-530.	1.2	6
2	The FORTA (Fit fOR The Aged) List 2021: Fourth Version of a Validated Clinical Aid for Improved Pharmacotherapy in Older Adults. Drugs and Aging, 2022, 39, 245-247.	1.3	25
3	The Sex-Specific Impact of the FORTA (Fit-fOR-The-Aged) List on Medication Quality and Clinical Endpoints in Older Hospitalized Patients: Secondary Analysis of a Randomized Controlled Trial. Drugs - Real World Outcomes, 2022, , 1.	0.7	0
4	Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty: a systematic review of randomized controlled trials. European Journal of Clinical Pharmacology, 2021, 77, 1-12.	0.8	26
5	Target profiling in terms of translatability and early translation planning. , 2021, , 123-132.		0
6	STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk): a Delphi study by the EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs. Age and Ageing, 2021, 50, 1189-1199.	0.7	88
7	The U.S.-FORTA (Fit fOR The Aged) List: Consensus Validation of a Clinical Tool to Improve Drug Therapy in Older Adults. Journal of the American Medical Directors Association, 2020, 21, 439.e9-439.e13.	1.2	33
8	The JAPAN-FORTA (Fit fOR The Aged) list: Consensus validation of a clinical tool to improve drug therapy in older adults. Archives of Gerontology and Geriatrics, 2020, 91, 104217.	1.4	11
9	FORTA(Fit-fOR-The-Aged)-based medication optimization: retrospective analysis of experiences from an unconventional outpatient service. European Geriatric Medicine, 2020, 11, 1035-1041.	1.2	3
10	A Structured Literature Review and International Consensus Validation of FORTA Labels of Oral Anticoagulants for Long-Term Treatment of Atrial Fibrillation in Older Patients (OAC-FORTA 2019). Drugs and Aging, 2020, 37, 539-548.	1.3	9
11	Calling for an exponential escalation scheme in vaccine development for COVID-19. European Journal of Clinical Pharmacology, 2020, 76, 1471-1472.	0.8	1
12	The Fit fOR The Aged (FORTA) project and its clinical implications. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 275-277.	1.5	3
13	Knowledge on and use of the FORTA (â€œFit fOR The Agedâ€)-list and the FORTA App by general practitioners in Baden-WÃ¼rttemberg, Germany. European Geriatric Medicine, 2020, 11, 499-503.	1.2	4
14	The FORTA (Fit fOR The Aged)-EPI (Epidemiological) Algorithm: Application of an Information Technology Tool for the Epidemiological Assessment of Drug Treatment in Older People. Drugs and Aging, 2019, 36, 969-978.	1.3	9
15	A systematic review and novel classification of listing tools to improve medication in older people. European Journal of Clinical Pharmacology, 2019, 75, 619-625.	0.8	42
16	The FORTA (Fit fOR The Aged) List 2018: Third Version of a Validated Clinical Tool for Improved Drug Treatment in Older People. Drugs and Aging, 2019, 36, 481-484.	1.3	56
17	Higher Fit-fOR-The-Aged (FORTA) Scores Comprising Medication Errors are Associated with Impaired Cognitive and Physical Function Tests in the VALFORTA Trial. Drugs and Aging, 2019, 36, 269-277.	1.3	9
18	Association of polypharmacy and hyperpolypharmacy with frailty states: a systematic review and meta-analysis. European Geriatric Medicine, 2019, 10, 9-36.	1.2	79

#	Article	IF	Citations
19	The EURO-FORTA (Fit fOR The Aged) List: International Consensus Validation of a Clinical Tool for Improved Drug Treatment in Older People. Drugs and Aging, 2018, 35, 61-71.	1.3	73
20	Rapid actions of aldosterone revisited: Receptors in the limelight. Journal of Steroid Biochemistry and Molecular Biology, 2018, 176, 94-98.	1.2	19
21	Changes in prescription patterns in older hospitalized patients: the impact of FORTA on disease-related over- and under-treatments. European Journal of Clinical Pharmacology, 2018, 74, 339-347.	0.8	17
22	Appropriateness of Oral Anticoagulants for the Long-Term Treatment of Atrial Fibrillation in Older People: Results of an Evidence-Based Review and International Consensus Validation Process (OAC-FORTA 2016). Drugs and Aging, 2017, 34, 499-507.	1.3	43
23	New Thieme Research Awards: Call for Pacesetting Contributions to Drug Research. Drug Research, 2017, 67, 137-137.	0.7	0
24	The FORTA (Fit fOR The Aged) App as a Clinical Tool to Optimize Complex Medications in Older People. Journal of the American Medical Directors Association, 2017, 18, 893.	1.2	8
25	Translatability score revisited: differentiation for distinct disease areas. Journal of Translational Medicine, 2017, 15, 226.	1.8	13
26	New Thieme Research Awards: Call for Pacesetting Contributions to Drug Research. Drug Research, 2017, 67, 256-256.	0.7	0
27	Older People, a Plethora of Drugs, and Drug List Approaches: Useful, Efficacious, or a Waste of Time?. Journal of the American Medical Directors Association, 2016, 17, 1073-1075.	1.2	8
28	VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification. Age and Ageing, 2016, 45, 262-267.	0.7	126
29	Treatment-dependent and treatment-independent risk factors associated with the risk of diabetes-related events: a retrospective analysis based on 229,042 patients with type 2 diabetes mellitus. Cardiovascular Diabetology, 2015, 14, 14.	2.7	23
30	Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age and Ageing, 2015, 44, 745-755.	0.7	105
31	Development of a Tool to Identify Patients' Preference for Vitamin K Antagonist or Direct Oral Anticoagulant Therapy. Seminars in Thrombosis and Hemostasis, 2014, 40, 121-128.	1.5	18
32	Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects. European Journal of Clinical Pharmacology, 2014, 70, 1159-1172.	0.8	137
33	Prevalence of renal insufficiency in hospitalised patients with venous thromboembolic events: A retrospective analysis based on 6,725 VTE patients. Thrombosis Research, 2014, 134, 1014-1019.	0.8	10
34	Initial anticoagulation therapy in patients with venous thromboembolism and impaired renal function: results of an observational study. Zeitschrift Fur Gesundheitswissenschaften, 2014, 22, 89-99.	0.8	3
35	The history of RRSH meetings (Rapid responses to steroid hormones). Steroids, 2014, 81, 2-3.	0.8	1
36	Morbus Diureticus in the Elderly: Epidemic Overuse of a Widely Applied Group of Drugs. Journal of the American Medical Directors Association, 2013, 14, 437-442.	1.2	47

#	Article	IF	Citations
37	Who Protects Physicians and Patients from Guidelines?. Cardiology, 2012, 121, 56-58.	0.6	1
38	Translatability scoring in drug development: eight case studies. Journal of Translational Medicine, 2012, 10, 39.	1.8	37
39	Drug development in the light of translational science: shine or shade?. Drug Discovery Today, 2011, 16, 1076-1083.	3.2	31
40	Challenges of Longevity in Developed Countries: Vascular Prevention of Dementia as an Immediate Clue to Tackle an Upcoming Medical, Social and Economic Stretch. Neurodegenerative Diseases, 2011, 8, 275-282.	0.8	7
41	Multimorbidity and polypharmacy: Which betablocker to use in relation to the pharmacokinetic profile and interaction potential. Arzneimittelforschung, 2010, 60, 57-63.	0.5	10
42	Review/PerspectiveTranslational Medicine: What is it and what could it be?. Arzneimittelforschung, 2009, 59, 3-7.	0.5	8
43	Assessing the translatability of drug projects: what needs to be scored to predict success?. Nature Reviews Drug Discovery, 2009, 8, 541-546.	21.5	114
44	Translational medicine: science or wishful thinking?. Journal of Translational Medicine, 2008, 6, 31.	1.8	66
45	To be or not to be (a receptor). Steroids, 2007, 72, 107-110.	0.8	10
46	Translational Science in Medicine. Pharmaceutical Medicine, 2006, 20, 303-310.	0.4	11
47	Nongenomic actions of estrogens: Exciting opportunities for pharmacology. Maturitas, 2006, 54, 321-326.	1.0	9
48	Non-genomic steroid hormone effects: Membrane or intracellular receptors?. Journal of Steroid Biochemistry and Molecular Biology, 2006, 102, 180-183.	1.2	87
49	Translational medicine: can it really facilitate the transition of research â€œfrom bench to bedsideâ€?. European Journal of Clinical Pharmacology, 2006, 62, 91-95.	0.8	80
50	Effects of Aldosterone and Mineralocorticoid Receptor Blockade on Intracellular Electrolytes. Heart Failure Reviews, 2005, 10, 39-46.	1.7	17
51	Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control?. Clinical Therapeutics, 2004, 26, A21-A27.	1.1	12
52	Meta-analysis of Flecainide Safety in Patients with Supraventricular Arrhythmias. Arzneimittelforschung, 2002, 52, 507-514.	0.5	27
53	Hypoxia modulates rapid effects of aldosterone on oxidative metabolism in human calf muscle. Journal of Endocrinological Investigation, 2001, 24, 587-597.	1.8	8
54	Chemical modification and structural analysis of the progesterone membrane binding protein from porcine liver membranes. Molecular and Cellular Biochemistry, 2001, 218, 71-79.	1.4	23

#	Article	IF	Citations
55	Interaction of Rapid Nongenomic Cardiovascular Aldosterone Effects with the Adrenergic System1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 761-767.	1.8	47
56	The Human Membrane Progesterone Receptor Gene: Genomic Structure and Promoter Analysis. DNA Sequence, 2001, 12, 13-25.	0.7	24
57	Moxonidine and Ramipril in Patients with Hypertension and Obstructive Pulmonary Disease. Clinical Drug Investigation, 2000, 20, 19-24.	1.1	3
58	Specific Progesterone Binding to a Membrane Protein and Related Nongenomic Effects on Ca2+-Fluxes in Sperm. Endocrinology, 1999, 140, 5999-6002.	1.4	114
59	The New Topical Steroid Ciclesonide Is Effective in the Treatment of Allergic Rhinitis. Journal of Clinical Pharmacology, 1999, 39, 1062-1069.	1.0	40
60	Biotin-Labelled and Photoactivatable Aldosterone and Progesterone Derivatives as Ligands for Affinity Chromatography, Fluorescence Immunoassays and Photoaffinity Labelling. FEBS Journal, 1996, 237, 514-518.	0.2	2
61	Purification and Partial Sequencing of High-Affinity Progesterone-Binding Site(s) from Porcine Liver Membranes. FEBS Journal, 1996, 239, 726-731.	0.2	250
62	Nongenomic Cardiovascular Effects of Triiodothyronine in Euthyroid Male Volunteers. , 0, .		15